Aica Ribonucleotide is a peptide whose technical name is 5-Aminoimidazole-4-carboxamide ribonucleotide. It is available for purchase for the purposes of scientific study on animal test subjects under several different names, such as ZMP, AICAR, and Acadesine. It is presented in white powder form, and contains a molecular weight of 338.211162. Aica Ribonucleotide is also referred to as Aicar online and in most research communities.
How Aica Ribonucleotide Works
According to scientific study on animal test subjects, Aica Ribonucleotide’s mechanics allow for the acceleration of metabolic processes within animal test subjects. These accelerations manifest themselves in the following methods:
- Increased glucose uptake – Aica Ribonucleotide has been determined to boost glycogen synthesis, which in turn leads to an increased synthesis of the proteins that are responsible for skeletal muscle building and repair.
- Decreased Insulin Resistance – The peptide contains the ability to be able to bock the receptors that would normally inhibit the intake of insulin; the peptide that is responsible for the causation of cells in the liver, skeletal muscles, and fat tissue to absorb glucose from the blood. This blocking of such inhibitions allows for an elevated take of glucose intake, which in turn allows for a more efficient energy conversion process. This in turn allows for an elevated rate of metabolic processes relating to the muscular and skeletal structures found in animal test subjects.
- More Efficient Regulation of Energy – Because of Aica Ribocluneotide’s ability to accelerate the synthesis of glycogen, scientific study on animal test subjects has determined that the peptide can control the distribution and usage of energy in a more efficient manner. This increased efficiency has been tied to several benefits as they relate to several functions regarding an animal test subjects’ body, including a boost of endurance and an increased facility to burn fat.
Aica Ribonucleotide’s Relationship with Cardiac Ischemic Injuries
While scientific research conducted on animal test subjects has determined that Aica Ribonucleotide’s ability to expedite the subjects’ metabolic processes, the peptide’s efficient nature has caused study to especially hone in on its potential effects relating to cardiac ischemic injuries.
At its base point, a cardiac ischemic injury is classified as an affliction whose cause is tied to a restriction of blood supply to tissues. This in turn causes an insufficient amount of glucose and oxygen to be delivered in order to maintain a regulated amount of cellular functionality within the heart muscle. Without proper cellular functionality, the heart starts to fail.
Primarily, cardiac ischemic injuries are directly brought on by a condition known as angina pectoris. This condition, routinely referred to as angina, is characterized by an insufficient amount of blood flow to the heart. This insufficient blood flow translates into an insufficient amount of oxygen and glucose being provided to heart muscle cells, which in turn causes the heart to malfunction. However, angina pectoris can sometimes be asymptomatic in its presentation. This condition could lead to a host of serious heart-related elements, up to and including cardiac arrest.
The scientific study based on animal test subjects has led to the theory that Aica Ribonucleotide’s ability to improve the metabolic processes within a subjects’ body would lessen the restriction of blood flow to the heart muscle, creating a more consistent sense of regulation in the process. This would theoretically enable a partially reduced risk of angina pectoris from occurring and, by extension, a reduced risk of heart failure. Additional theories based on such scientific study on animal test subjects link the peptide as a potential ally in regards to treating a heart attack that was caused by a cardiac ischemic episode. The reason for this theory also ties to Aica Ribonucleotide’s ability to lessen the restriction of blood flow to the heart, as an increase in blood flow – and subsequently and increase in glucose and oxygen getting to cardiac cells – would aid in stabilizing the heart as it recovers from an ischemic episode.
Other Notes on Aica Ribonucleotide’s Functionality
There are two things that should be noted in relation to Aica Ribonucleotide’s usage and functionality. The first is that scientific study on animal test subjects has determined that a few side effects have been linked to the peptide, including some serious side effects linked to the heart muscle. The more serious side effects include:
- Development of heart valve defects
- Pulmonary hypertension
- Abnormal growth of heart tissue
Secondly, it should be noted that Aica Ribonucleotide is currently in the research phase. Any study or research based on the peptide should be relegated to animal test subjects and within the strict confines of a controlled environment such as a medical research facility or a laboratory.